Alpha-lipoic acid (R-ALA)
Mitochondrial cofactor studied for symptoms of diabetic neuropathy: one 5-week RCT lowered symptom scores at oral 600 mg/day.
- Evidence
- Moderate evidenceGRADE certainty: Moderate
- Typical dose
- R-ALA or racemic ALA: 600 mg/day, single dose on empty stomach
- Time to effect
- Symptom scores fell within a 5-week trial
- Safety
- Has documented cautions
Evidence ratings summarise published research on Alpha-lipoic acid (R-ALA) in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.
Ask about Alpha-lipoic acid (R-ALA)
Interactions
Taking any medication?
Check Alpha-lipoic acid (R-ALA) against it.
Why
Alpha-lipoic acid (thioctic acid) is an endogenous mitochondrial cofactor and broad-spectrum antioxidant. In a 5-week placebo-controlled RCT in 181 people with diabetic polyneuropathy, oral 600 mg/day lowered the total symptom score (stabbing and burning pain, paraesthesia, numbness) more than placebo; higher doses added no clear benefit and caused more nausea, vomiting and vertigo. Longer-term effects are not shown.
How it works
Cofactor for pyruvate and α-ketoglutarate dehydrogenase complexes in mitochondrial energy metabolism. Regenerates vitamins C and E, glutathione, and CoQ10 (the antioxidant network). Chelates redox-active metals.
Expected onset · Symptom scores fell within a 5-week trial
How to take
Dosage
R-ALA or racemic ALA: 600 mg/day, single dose on empty stomach. Higher doses (up to 1,800 mg/day) studied in shorter trials.
Timing
Morning, on empty stomach 30 min before food
On the label
R-(+)-alpha-lipoic acid is the bioactive enantiomer. 'Stabilised R-ALA' or 'Na-RALA' has better bioavailability than racemic forms.
Studied in
Adults with symptomatic diabetic peripheral neuropathy.
Safety
Evidence
Ziegler 2006 Diabetes Care RCT (n=181): in people with diabetic polyneuropathy, oral alpha-lipoic acid 600 mg daily for 5 weeks lowered the total symptom score (stabbing and burning pain, paresthesia, numbness) more than placebo; 62% versus 26% had at least a 50% reduction. Higher doses added no clear extra benefit and caused more nausea, vomiting and vertigo.
GRADE certainty: Moderate — rated by Healicus using the GRADE method
Questions people ask
Does Alpha-lipoic acid (R-ALA) work?
Ziegler 2006 Diabetes Care RCT (n=181): in people with diabetic polyneuropathy, oral alpha-lipoic acid 600 mg daily for 5 weeks lowered the total symptom score (stabbing and burning pain, paresthesia, numbness) more than placebo; 62% versus 26% had at least a 50% reduction. Higher doses added no clear extra benefit and caused more nausea, vomiting and vertigo. Certainty of the evidence: Moderate, rated by Healicus using the GRADE method.
How is Alpha-lipoic acid (R-ALA) taken?
R-ALA or racemic ALA: 600 mg/day, single dose on empty stomach. Higher doses (up to 1,800 mg/day) studied in shorter trials. Timing: Morning, on empty stomach 30 min before food. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.
Are there interactions or cautions?
Can cause hypoglycaemia; adjust diabetes medication monitoring if combining with insulin or sulphonylureas. Rare insulin autoimmune syndrome (insulin antibodies) reported in East Asian populations. Theoretical thiamine depletion with chronic high-dose use. Documented drug and supplement interactions can be looked up in the free interaction reference.
What is the evidence based on?
Sources: Ziegler et al., Diabetes Care 2006, SYDNEY 2 trial: oral alpha-lipoic acid 600/1200/1800 mg in diabetic polyneuropathy (RCT).
One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.